StockData

Globavend vs Cellyan Biotechnology

GVH and HKPD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GVH and HKPD compare

Globavend grew revenue faster over the last twelve months (42.5% versus −33.9% for Cellyan Biotechnology).

Globavend keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −8.5% at Cellyan Biotechnology.

Globavend scores higher on the StockData Score (9 against 3 for Cellyan Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGVHHKPD
Size and price
Share price$0.772$1.52
Change, 1 year−80.4%−93.5%
Beta (5Y)2.71–
Employees92
StockData Score
Total score9 (better)3
Valuation score00
Growth score1 (better)0
Performance score3 (better)1
Health score5 (better)2
Dividend score00
Growth
Revenue growth (TTM)42.5% (better)−33.9%
Net income growth (TTM)−49.0%–
EPS growth (TTM)−91.2%–
Profitability
Gross margin10.1%10.3% (better)
Operating margin4.1% (better)−17.8%
Net margin2.9% (better)−8.5%
FCF margin0.98% (better)−5.9%
Return on equity8.5% (better)−15.5%
Return on invested capital18.6% (better)−22.5%
Financial health
Debt / equity0.000.09 (better)
Interest coverage963× (better)−17.8×
Current ratio9.95 (better)3.86
Piotroski F-score4 (better)3
Ownership
Held by institutions1.3%1.5%
Held by insiders7.8%81.9%
Insider net buying, 12 months$4.2K–
Short interest, % of float1.4%0.57%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.